Clinical diagnosis of Alzheimer's disease¶
Why this mattered¶
Before McKhann et al. (1984), Alzheimer’s disease was difficult to treat as a consistent clinical entity during life: definitive diagnosis depended on neuropathology, while living patients were often described under broad or inconsistent dementia labels. The paper’s major shift was to formalize Alzheimer’s disease as a clinically diagnosable syndrome, defined by insidious onset, progressive memory and cognitive decline, absence of early focal neurologic signs, and systematic exclusion of other causes. Its categories of probable, possible, and definite Alzheimer’s disease gave clinicians and researchers a shared language for degrees of diagnostic certainty.
That shared language made large-scale Alzheimer’s research newly tractable. Patients could be enrolled into studies using comparable criteria, followed longitudinally, and separated from other dementias with greater consistency. This helped standardize clinical trials, epidemiologic estimates, neuropsychological assessment, and clinicopathologic correlation studies. The paper did not claim that laboratory tests could diagnose Alzheimer’s disease; rather, it placed them in a supporting role, mainly to rule out alternative causes. That distinction was crucial because it made the criteria usable before biomarkers were available.
The framework also shaped later breakthroughs by giving biomarker and imaging research a clinical reference point to improve upon. Subsequent advances in MRI, PET imaging, cerebrospinal-fluid assays, amyloid and tau biomarkers, and eventually biologically defined research criteria all emerged against the background of the 1984 clinical standard. In that sense, the paper mattered not because it solved diagnosis permanently, but because it created the operational foundation from which Alzheimer’s disease could become a coherent target for modern neuroscience, therapeutic trials, and biomarker-based redefinition.
Abstract¶
Clinical criteria for the diagnosis of Alzheimer's disease include insidious onset and progressive impairment of memory and other cognitive functions. There are no motor, sensory, or coordination deficits early in the disease. The diagnosis cannot be determined by laboratory tests. These tests are important primarily in identifying other possible causes of dementia that must be excluded before the diagnosis of Alzheimer's disease may be made with confidence. Neuropsychological tests provide confirmatory evidence of the diagnosis of dementia and help to assess the course and response to therapy. The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information become available.
Related¶
- cite → “Mini-mental state” — The Alzheimer's diagnostic criteria cite the Mini-Mental State Examination as a brief cognitive screening tool for assessing dementia.
- enables ← “Mini-mental state” — The Mini-Mental State Examination supplied a standardized cognitive screening measure, enabling Alzheimer's diagnostic criteria to operationalize dementia assessment.